---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009867"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:47:29.776992+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M

## Summary
- Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.
- Full year 2025 preliminary revenue ~$37M.
- FY2026 revenue guided at $54-60M, driven by organic growth and IRRA flow product integration.
- Q4 segment growth: functional neurosurgery disposables +23%, biologics/drug delivery +26%.
- Preliminary results subject to revision; audited results expected later in Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-009867
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312526009867/0001193125-26-009867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312526009867/clpt-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009867
- JSON: https://secwatch.observer/filing/0001193125-26-009867.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.